Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy

CXCL13型 医学 阶段(地层学) 免疫疗法 肿瘤科 趋化因子 内科学 癌症免疫疗法 癌症 膀胱癌 免疫学 生物 趋化因子受体 受体 古生物学
作者
Clarice S. Groeneveld,Jacqueline Fontugne,Luc Cabel,Isabelle Bernard‐Pierrot,François Radvanyi,Yves Allory,Aurélien de Reyniès
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:148: 181-189 被引量:153
标识
DOI:10.1016/j.ejca.2021.01.036
摘要

Immune checkpoint inhibitors (ICIs) have proved to be an effective treatment for up to 40% of muscle-invasive bladder cancer (MIBC), but there is still a need for better performing biomarkers allowing to improve prediction of response to ICI. Response to immunotherapy in soft-tissue sarcoma, melanoma and renal cell carcinoma have been recently linked to the presence of tertiary lymphoid structures (TLS) in the tumour. TLS are organised aggregates of T, B and dendritic cells, participating in adaptive antitumor immune response. The chemokine CXCL13 is involved in the formation of TLS, and is reported as a reliable transcriptomic marker of TLS.In this study, we sought to assess whether CXCL13 transcript expression can be a prognostic biomarker for ICI-treated MIBC patients and also investigated whether it can serve a biomarker of TLS in MIBC.We analysed transcriptomic data from three publicly available MIBC cohorts and evaluated pathological slides from the TCGA-BLCA cohort for TLS presence and stage of maturation.We showed that CXCL13 was independently associated with both prolonged survival (HR = 0.8, 95% CI [0.68-0.94]) and objective response (p < 0.0001) in patients treated with ICI, at the difference of others immunological signatures. However, it was not a predictor for non-ICI-treated MIBC, suggesting a predictive effect of ICI efficacy. Finally, we validated that CXCL13 expression was correlated with tumour TLS in TCGA data set (p < 0.001), and can serve as a marker of TLS in bladder cancer.These results support that CXCL13 expression, as a surrogate for tumour TLS, is a relevant candidate predictive biomarker of response to ICI for patients with advanced-stage bladder cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
洁净雅彤发布了新的文献求助10
2秒前
平淡远航完成签到,获得积分10
2秒前
所所的应助被开心德地采纳,获得10
2秒前
JackieLiu的应助被简单亦寒采纳,获得30
3秒前
3秒前
泥头车完成签到,获得积分10
3秒前
liy发布了新的文献求助30
3秒前
3秒前
3秒前
4秒前
Lee完成签到,获得积分10
4秒前
molihuakai的应助被好吃懒做采纳,获得10
4秒前
猪猪侠完成签到,获得积分10
4秒前
火的信仰完成签到,获得积分10
5秒前
小回忆完成签到,获得积分10
6秒前
bkagyin的应助被小宇采纳,获得10
7秒前
7秒前
7秒前
7秒前
7秒前
落子无悔关注了科研通微信公众号
8秒前
钪锵玫瑰完成签到 ,获得积分10
8秒前
弦越的应助被吕培森采纳,获得10
9秒前
9秒前
虎虎完成签到,获得积分10
10秒前
11秒前
大个的应助被开心德地采纳,获得10
11秒前
My_magnum_opus发布了新的文献求助150
12秒前
12秒前
科研通AI65的应助被笑ige采纳,获得10
12秒前
14秒前
科研通AI6.2的应助被wwrrqq采纳,获得10
14秒前
小满完成签到,获得积分10
15秒前
wall完成签到 ,获得积分10
15秒前
我是谁的应助被LUO采纳,获得30
16秒前
碎觉觉发布了新的文献求助10
17秒前
snow发布了新的文献求助10
18秒前
科研通AI6.2的应助被cds采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188451
求助须知:如何正确求助?哪些是违规求助? 9576286
关于积分的说明 21846376
捐赠科研通 7786514
什么是DOI,文献DOI怎么找? 3435343
关于科研通互助平台的介绍 2559618
邀请新用户注册赠送积分活动 2482322